LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

Search

Biogen Inc

Open

SectorGezondheidszorg

137.98 0.41

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

135.28

Max

137.65

Belangrijke statistieken

By Trading Economics

Inkomsten

394M

635M

Verkoop

215M

2.6B

K/W

Sectorgemiddelde

13.46

35.69

EPS

3.02

Winstmarge

23.995

Werknemers

7,605

EBITDA

457M

1B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+21.72% upside

Dividenden

By Dow Jones

Volgende Winsten

29 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.9B

21B

Vorige openingsprijs

137.57

Vorige sluitingsprijs

137.98

Nieuwssentiment

By Acuity

50%

50%

131 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Biogen Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 sep 2025, 18:25 UTC

Belangrijke Marktbewegers

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

28 sep 2025, 23:48 UTC

Marktinformatie

Nikkei May Rise After Friday's Stock Gains on Wall Street -- Market Talk

28 sep 2025, 23:48 UTC

Marktinformatie

Global Equities Roundup: Market Talk

28 sep 2025, 23:45 UTC

Marktinformatie

Gold Rises Amid Fed Rate-Cut Hopes -- Market Talk

28 sep 2025, 23:34 UTC

Marktinformatie

Oil Falls on Likely Technical Correction -- Market Talk

27 sep 2025, 04:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

26 sep 2025, 21:56 UTC

Acquisities, Fusies, Overnames

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26 sep 2025, 20:54 UTC

Winsten

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26 sep 2025, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

26 sep 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

26 sep 2025, 20:27 UTC

Acquisities, Fusies, Overnames

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 sep 2025, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

26 sep 2025, 19:54 UTC

Marktinformatie

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26 sep 2025, 19:53 UTC

Acquisities, Fusies, Overnames

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 sep 2025, 19:40 UTC

Winsten

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26 sep 2025, 19:24 UTC

Marktinformatie

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26 sep 2025, 19:17 UTC

Marktinformatie

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26 sep 2025, 19:15 UTC

Marktinformatie

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26 sep 2025, 19:03 UTC

Marktinformatie

Global Equities Roundup: Market Talk

26 sep 2025, 19:03 UTC

Marktinformatie

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26 sep 2025, 18:50 UTC

Marktinformatie
Winsten

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26 sep 2025, 18:36 UTC

Marktinformatie

Silver Closes Out Week With Strong Surge -- Market Talk

26 sep 2025, 18:02 UTC

Acquisities, Fusies, Overnames

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26 sep 2025, 18:02 UTC

Acquisities, Fusies, Overnames

ING: Global Development Hasn't Received All Necessary Approvals >ING

26 sep 2025, 18:02 UTC

Acquisities, Fusies, Overnames

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26 sep 2025, 17:54 UTC

Marktinformatie

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26 sep 2025, 16:56 UTC

Marktinformatie
Winsten

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26 sep 2025, 16:41 UTC

Marktinformatie
Winsten

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26 sep 2025, 16:26 UTC

Winsten

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26 sep 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Biogen Inc Prognose

Koersdoel

By TipRanks

21.72% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 167.2 USD  21.72%

Hoogste 224 USD

Laagste 118 USD

Gebaseerd op 26 Wall Street-analisten die 12-maands prijsdoelen bieden voor Biogen Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

26 ratings

12

Buy

14

Hold

0

Sell

Technische score

By Trading Central

118.15 / 121.17Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

131 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat